Processing

Please wait...

Settings

Settings

Goto Application

1. WO2006099142 - PROGNOSTIC METHOD FOR VASCULAR DISEASES

Publication Number WO/2006/099142
Publication Date 21.09.2006
International Application No. PCT/US2006/008602
International Filing Date 10.03.2006
IPC
C12Q 1/68 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
CPC
C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
C12Q 2600/106
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q 2600/156
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
156Polymorphic or mutational markers
C12Q 2600/172
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
172Haplotypes
G16B 20/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
20ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 40/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
40ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Applicants
  • THE TRUSTEES OF BOSTON UNIVERSITY [US]/[US] (AllExceptUS)
  • CHILDREN'S MEDICAL CNETER CORPORATION [US]/[US] (AllExceptUS)
  • SEBASTIANI, Paola [IT]/[US] (UsOnly)
  • BALDWIN, Clinton, T. [US]/[US] (UsOnly)
  • STEINBERG, Martin, H. [US]/[US] (UsOnly)
  • RAMONI, Marco, F. [IT]/[US] (UsOnly)
Inventors
  • SEBASTIANI, Paola
  • BALDWIN, Clinton, T.
  • STEINBERG, Martin, H.
  • RAMONI, Marco, F.
Agents
  • EISENSTEIN, Ronald
Priority Data
60/660,24310.03.2005US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PROGNOSTIC METHOD FOR VASCULAR DISEASES
(FR) PROCEDE POUR LE PRONOSTIC DE MALADIES VASCULAIRES
Abstract
(EN)
The present invention is directed to a group of genes and genetic polymorphisms that can be used to screen for individuals who are at high risk of developing a vascular disease, disorder or condition, such as cranio-vascular disease, including vascular occlusion, and overt stroke. The method comprises analysis of at least one marker in at least one of the genes of ADCY9 (NMJ)Ol 116); ANXA2 (NMJ)Ol 002858); BMP6 (NM_001718); CCL2 (NM_002982); CSF2 (NM_000758); ECEl (NM_001397 or its transcription variant NMJ 82918); ERG (NM_004449); MET (NM_000245); SELP (NM_003005); TEK (NM_000459); and TGFBR3 (NM_003243. When 5 or fewer of the genes are included in the analysis, it is preferable that one includes markers for at least SELP or BMP6 in the analysis. The invention is further directed to methods of predicting individuals at risk of specific diseases or disorders in a population using nucleic acid polymorphisms and Bayesian network analysis.
(FR)
L'invention concerne un groupe de gènes et des polymorphismes génétiques pouvant être utilisés pour détecter les sujets présentant un fort risque de développer une maladie, un trouble ou une affection vasculaires tels que la maladie cranio-vasculaire, y compris l'occlusion vasculaire et l'accident vasculaire cérébral manifeste. Le procédé comprend l'analyse d'au moins un marqueur dans au moins un des gènes de ADCY9 (NM_001116); ANXA2 (NM_001002858); BMP6 (NM_001718); CCL2 (NM_002982); CSF2 (NM_000758); ECE1 (NM_001397 ou sa variante de transcription NM_182918); ERG (NM_004449); MET (NM_000245); SELP (NM_003005); TEK (NM_000459); and TGFBR3 (NM_003243). Lorsqu'un nombre inférieur ou égal à 5 de ces gènes est inclus dans l'analyse, il est préférable qu'un de ceux-ci comprenne des marqueurs pour au moins SELP ou BMP6 dans l'analyse. L'invention concerne de plus des procédés permettant de prédire dans une population les sujets à risque pour des maladies ou des troubles spécifiques, à l'aide de polymorphismes d'acides nucléiques et d'une analyse de réseau bayésien.
Also published as
EP6737751
Latest bibliographic data on file with the International Bureau